Jean-Jacques Bienaimé, BioMarin CEO (via YouTube)
BioMarin lays off 120 staffers to 'simplify' the company while FDA reviews its big gene therapy
By the time the FDA hands down its decision on valrox, BioMarin will be a different company — literally.
The biotech is laying off about 120 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
